Page last updated: 2024-11-06

lysergic acid diethylamide and Parkinson Disease

lysergic acid diethylamide has been researched along with Parkinson Disease in 2 studies

Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, MR1
Nichols, D1

Other Studies

2 other studies available for lysergic acid diethylamide and Parkinson Disease

ArticleYear
The history of ergot of rye (Claviceps purpurea) III: 1940-80.
    The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:1

    Topics: Bromocriptine; Claviceps; Dihydroergocryptine; Ergot Alkaloids; History, 20th Century; Humans; Lyser

2010
Legal highs: the dark side of medicinal chemistry.
    Nature, 2011, Jan-06, Volume: 469, Issue:7328

    Topics: Amphetamines; Animals; Depression; Designer Drugs; Drug Design; Electronic Mail; Hallucinogens; Huma

2011